Andrew Walding
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework.
Journal: British journal of cancer
Published: January 16, 2026
Camizestrant causes reversible pharmacological effects on retinal responses in rats.
Journal: Translational oncology
Published: April 03, 2025
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.
Journal: Future oncology (London, England)
Published: February 28, 2025
Correction to: Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions.
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: March 24, 2022
Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions.
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: January 10, 2022
Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 02, 2021
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.
Journal: Future oncology (London, England)
Published: July 19, 2021
How patients being treated for non-small cell lung cancer value treatment benefit despite side effects.
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: May 13, 2021
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Journal: Targeted oncology
Published: January 27, 2021
Cardiac Safety of Osimertinib: A Review of Data.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 28, 2020
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 25, 2019
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.
Journal: Japanese journal of clinical oncology
Published: October 05, 2018
Last Updated: 09/26/2026